In conclusion, our study emphasizes the Nrf2-Keap1 pathway as a potential therapeutic target in HCC, and in the absence of specific inhibitors of Nrf2, suggests that p62 targeting may represent a promising therapeutic alternative. Here, KEAP1 is linked to hepatocellular carcinoma.